Investor Presentation Full Year 2021
29
Investor presentation Full year 2021
Novo NordiskⓇ
The future of R&D is to focus on increasing the number of clinical
assets while maintaining industry-leading late-stage success
R&D investments will expand
beyond historic focus
Increased clinical assets
driving R&D investment
Pipeline
assets
Industry-leading success rate¹ from
any phase to market
Success
rate
100%
Biopharm
NASH
Diabetes
Obesity
I
CVD
CKD
Devices
180
Stem Cells
ILLUSTRATIVE
ILLUSTRATIVE
80%
60%
40%
20%
2019
Phase 1
Phase 2
Phase 3
Submission
0%
Future
Phase 1
Phase 2
Phase 3
Novo
Nordisk
Industry
range
__ Industry
average
Submission
NASH: Non-alcoholic steatohepatitis; CVD: Cardiovascular disease; CKD: Chronic kidney disease. Probabilities of success to market were calculated using substances entering phase between 2008 and 2014 and year of assessment 2017. Source: CMR
International, 2017
FutureView entire presentation